Latest News - Abbott Laboratories
Top Corporates Hub
Abbott Laboratories
Dexcom Stock, Down 13%, Haunted By Its 'Surprisingly Cautious' Outlook
31.10.2025 13:02
Dexcom's solid third-quarter report was overshadowed Friday by its "surprisingly cautious" outlook, and Dexcom stock tumbled.
Looking to Diversify Out of the AI Trade? Buy Boston Scientific Stock.
30.10.2025 12:38
The AI rally has many investors wondering where to turn in anticipation of its end. The medical-device maker is one solid option.
The Zacks Analyst Blog Highlights International Business Machines, Micron and Abbott
30.10.2025 09:26
Zacks analysts highlight IBM, Micron, and Abbott for their innovation-driven growth, solid fundamentals, and evolving market strategies.
Cardiovascular Repair & Reconstruction Devices - Global Market Forecast (2025-2032) Featuring Profiles of Medtronic, Edwards Lifesciences, Abbott Labs, Boston Scientific, Terumo and More
27.10.2025 12:30
The cardiovascular repair market is fueled by an aging population, technological advancements, and the rise in comorbidities. Opportunities lie in innovative, minimally invasive devices, value-based contracting, and regional market dynamics. Emphasizing personalized, data-driven solutions and supply chain resilience is crucial for growth. Cardiovascular Repair & Reconstruction Devices Market Cardiovascular Repair & Reconstruction Devices Market Dublin, Oct. 27, 2025 (GLOBE NEWSWIRE) -- The "Card
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock
22.10.2025 13:00
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Protein Supplements Market Forecast Report 2025-2030 | Clean-Label Protein Supplements Surge as Consumers Demand Transparency and Quality
22.10.2025 08:04
There's a shift towards plant-based sources like pea, soy, and quinoa, appealing to clean-label and allergen-free seekers. Innovations such as ready-to-drink beverages and gummies are expanding market appeal. North America leads, backed by strong fitness culture, while APAC shows the fastest growth. The market is highly fragmented with key players like Abbott, Glanbia, and Nestlé. E-commerce platforms are transforming distribution, offering convenience and variety. Global Protein Supplements Mar
The 5 Most Interesting Analyst Questions From Abbott Laboratories’s Q3 Earnings Call
22.10.2025 05:32
Abbott Laboratories’ third quarter results met Wall Street’s expectations for both revenue and non-GAAP profit, but the market reacted negatively, with shares declining over 4%. Management pointed to double-digit growth in medical devices, led by diabetes care and electrophysiology, as key drivers for the quarter. CEO Robert Ford commented that “recently launched new products generated nearly $5 billion in sales this quarter,” highlighting the contribution of new offerings. However, ongoing head
Functional Foods Forecast and Company Analysis Report 2025: A $678.32 Billion Market by 2033 Featuring Abbott, Amway, BASF, Cargill, Clif Ba, Danone, General Mills, Kellogg, Kerry, Nestle
21.10.2025 12:58
The Global Functional Foods Market is set to expand at a CAGR of 7.92% from 2025 to 2033, reaching $678.32 billion by 2033, up from $341.6 billion in 2024. The surge is driven by increasing health awareness, demand for fortified foods, and an emphasis on preventive healthcare. Functional foods, enhanced with vitamins, minerals, and probiotics, are gaining traction among health-conscious consumers aiming to prevent chronic diseases. Key markets include the U.S., Germany, and India, with bakery an
Abbott Laboratories (ABT) Rated Buy as Benchmark Highlights Diagnostics Growth and Global Resilience
21.10.2025 10:33
Abbott Laboratories (NYSE:ABT) ranks among the best medical device stocks to invest in. Benchmark began coverage of Abbott Laboratories (NYSE:ABT) on October 10 with a $145 price target and a Buy rating, describing the company as a reliable performer in a dynamic global environment. The firm claims that Abbott’s business strategy is unique in that […]
Did Mixed Segment Results and Narrowed Guidance Just Shift Abbott Laboratories' (ABT) Investment Narrative?
21.10.2025 08:10
In October 2025, Abbott Laboratories reported third-quarter results showing US$11.37 billion in sales and reaffirmed its 2025 earnings guidance, narrowing expected full-year adjusted diluted EPS to US$5.12–US$5.18, while guiding for organic sales growth of 7.5%–8.0% excluding COVID-19 testing. Despite strong medical device sales, the company faced mixed results due to challenges in its diagnostics and nutrition segments, prompting investors to focus closely on its revised annual outlook and...
Abbott and BIG CARiNG Group Launch Nationwide Influenza Awareness Program to Strengthen Public Health Response Through Early Intervention
21.10.2025 05:12
Abbott, a global healthcare leader, and BIG CARiNG Group (BCG), one of Malaysia's largest retail pharmacies, announced a strategic three-year collaboration to promote influenza awareness across Malaysia. The Influenza Awareness Program, running from 2025 to 2027, is designed to elevate public understanding of influenza and encourage proactive health management.
Abbott: GLP-1 Beneficiary - A Dividend Raise May Be Coming
18.10.2025 09:39
Abbottâs FY2025 guidance shows robust growth driven by diabetes care, new product launches, and strong demand. Find out why ABT stock is a buy.
Abbott Labs' Business Momentum Intact Despite Mixed Q3, RBC Says
16.10.2025 15:31
Abbott Laboratories' (ABT) underlying business momentum is intact heading into 2026 despite mixed Q3
Abbott’s strong Q3 medtech performance offset by diagnostic weakness
16.10.2025 11:49
Abbott narrowly missed analysts’ expectations of $11.4bn for Q3 2025, with diminished Covid-19 test demand and China headwinds impacting overall performance.